Neoral Soft Gelatin Capsules ( DrugBank: Gelatin )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
| 269 | Pyogenic arthritis | 2 |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-001968-36-GB (EUCTR) | 27/08/2008 | 15/07/2008 | Comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: a Trial - CONSTRUCT | Comparison of infliximab and ciclosporin in steroid resistant ulcerative colitis: a Trial - CONSTRUCT | Acute severe steroid resistant ulcerative colitis MedDRA version: 14.1;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders | Trade Name: Remicade Trade Name: Sandimmun Trade Name: Neoral Soft Gelatin Capsules | Swansea University | NULL | Not Recruiting | Female: yes Male: yes | 250 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no | United Kingdom |
269. Pyogenic arthritis
Clinical trials : 24 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-008291-14-IE (EUCTR) | 31/03/2010 | 08/10/2009 | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | pyoderma gangrenosum MedDRA version: 9.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum MedDRA version: 9.1;Classification code 10037635;Term: Pyoderma gangrenosum | Trade Name: Neoral soft gelatin capsules INN or Proposed INN: CICLOSPORIN Trade Name: Neoral Oral Solution INN or Proposed INN: CICLOSPORIN Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE | Nottingham University Hospitals NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | United Kingdom;Ireland | ||||
| 2 | EUCTR2008-008291-14-GB (EUCTR) | 14/05/2009 | 22/05/2009 | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | pyoderma gangrenosum MedDRA version: 14.0;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | Trade Name: Neoral soft gelatin capsules INN or Proposed INN: CICLOSPORIN Trade Name: Neoral Oral Solution INN or Proposed INN: CICLOSPORIN Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE | Nottingham University Hospitals NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 140 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | Ireland;United Kingdom |